Lisata Therapeutics, Inc.
LSTANASDAQHealthcare● Active
$3.48
+$0.13(+3.88%)
Market Cap$31690237
P/E Ratio—
52W High$5.07
52W Low$1.81
Lisata Therapeutics, Inc. (LSTA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LSTA · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.50
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
✓ 3-Quarter EPS Beat Streak
LSTA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.06
Rev. $1.94B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.06
Rev. Est.$1.94B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | — | — | — | — | — | — |
| — Q2 FY2026 | May 11, 2026 | — | -$0.50 | — | — | $0.00B | — |
| ▲ Q1 FY2026 | Mar 12, 2026 | -$0.51 | -$0.33 | +35.3% | $0.00B | $0.00B | +0.0% |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.54 | -$0.49 | +9.3% | — | — | — |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.65 | -$0.54 | +16.9% | $0.00B | — | — |
| ▼ Q2 FY2025 | May 8, 2025 | -$0.53 | -$0.55 | -3.8% | — | — | — |
| ▲ Q1 FY2025 | Feb 27, 2025 | -$0.76 | -$0.55 | +27.6% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.75 | -$0.59 | +21.3% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026
EPS Actual
-$0.50
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 12, 2026Beat
EPS Actual
-$0.33
EPS Est.
-$0.51
EPS Surpr.
+35.3%
Revenue
$0.00B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.49
EPS Est.
-$0.54
EPS Surpr.
+9.3%
Revenue
—
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.54
EPS Est.
-$0.65
EPS Surpr.
+16.9%
Revenue
$0.00B
Q2 FY2025
May 8, 2025Miss
EPS Actual
-$0.55
EPS Est.
-$0.53
EPS Surpr.
-3.8%
Revenue
—
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
-$0.55
EPS Est.
-$0.76
EPS Surpr.
+27.6%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.59
EPS Est.
-$0.75
EPS Surpr.
+21.3%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2025 | $-0.51 | $-0.51 | $-0.51 | 1 |
| Q3 FY2025 | $-0.55 | $-0.54 | $-0.51 | 2 |
| Q1 FY2021 | $-1.13 | $-1.13 | $-1.13 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2021 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | May 11, 2026 | — | $3.15 | $3.26 | +3.49% |
| ▲ Q1 FY2026 | Mar 12, 2026 | +35.3% | $5.03 | $5.03 | +0.00% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +9.3% | $2.34 | $2.35 | +0.43% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +16.9% | $2.96 | $2.80 | -5.41% |
| ▼ Q2 FY2025 | May 8, 2025 | -3.8% | $2.30 | $2.37 | +3.04% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +27.6% | $2.39 | $2.40 | +0.42% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +21.3% | $2.90 | $2.91 | +0.34% |
| ▲ Q3 FY2024 | Aug 12, 2024 | +18.7% | $2.92 | $2.93 | +0.34% |
Q2 FY2026+3.49%
Report Date
May 11, 2026
EPS Beat/Miss
—
Price Before
$3.15
Price After
$3.26
Q1 FY2026+0.00%
Report Date
Mar 12, 2026
EPS Beat/Miss
+35.3%
Price Before
$5.03
Price After
$5.03
Q4 FY2025+0.43%
Report Date
Nov 6, 2025
EPS Beat/Miss
+9.3%
Price Before
$2.34
Price After
$2.35
Q3 FY2025-5.41%
Report Date
Aug 7, 2025
EPS Beat/Miss
+16.9%
Price Before
$2.96
Price After
$2.80
Q2 FY2025+3.04%
Report Date
May 8, 2025
EPS Beat/Miss
-3.8%
Price Before
$2.30
Price After
$2.37
Q1 FY2025+0.42%
Report Date
Feb 27, 2025
EPS Beat/Miss
+27.6%
Price Before
$2.39
Price After
$2.40
Q4 FY2024+0.34%
Report Date
Nov 12, 2024
EPS Beat/Miss
+21.3%
Price Before
$2.90
Price After
$2.91
Q3 FY2024+0.34%
Report Date
Aug 12, 2024
EPS Beat/Miss
+18.7%
Price Before
$2.92
Price After
$2.93
Avg Beat Reaction-0.65%
Avg Miss Reaction+3.04%
Beat Rate6 / 8 quarters
Largest Move-5.41% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LSTA ends December
Lisata Therapeutics, Inc. (LSTA) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.50 (in line with the analyst consensus of —). LSTA has beaten EPS estimates for 3 consecutive quarters. The next LSTA earnings date is expected around September 1, 2026.
Each quarter, investors track LSTA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LSTA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LSTA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LSTA earnings · 4 questionsLisata Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. LSTA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LSTA historically reports after market close (AMC).
LSTA earnings datewhen is LSTA earningsLSTA next earnings datewhen does LSTA report earningsLSTA earnings calendar
▸ Source: FMP · Lisata Therapeutics, Inc. SEC filings · US GAAP · Lisata Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026